Last $64.25 USD
Change Today +0.53 / 0.83%
Volume 5.6M
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for eli lilly & co (LLY)

Year over year, Eli Lilly and Company has seen revenues remain relatively flat ($22.6B USD to $23.1B USD), though the company was able to grow net income from $4.1B USD to $4.7B USD. A reduction in the percentage of sales devoted to selling, general and administrative costs from 33.24% to 30.83% was a key component in the bottom line growth in the face of flat revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Reclassified
Dec 31
2011
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues23,076.024,286.522,603.423,113.1
TOTAL REVENUES23,076.024,286.522,603.423,113.1
Cost of Goods Sold4,366.25,067.94,796.54,908.1
GROSS PROFIT18,709.819,218.617,806.918,205.0
Selling General & Admin Expenses, Total7,053.47,879.97,513.57,125.6
R&D Expenses4,884.25,020.85,278.15,531.3
OTHER OPERATING EXPENSES, TOTAL11,937.612,900.712,791.612,656.9
OPERATING INCOME6,772.26,317.95,015.35,548.1
Interest Expense-185.5-186.0-177.8-160.1
Interest and Investment Income51.979.9105.0119.7
NET INTEREST EXPENSE-133.6-106.1-72.8-40.4
Currency Exchange Gains (Loss)-12.0-97.435.8-15.4
Other Non-Operating Income (Expenses)34.745.9-148.245.2
EBT, EXCLUDING UNUSUAL ITEMS6,661.36,160.34,830.15,537.5
Merger & Restructuring Charges-142.0-316.4-74.5-120.6
Gain (Loss) on Sale of Investments105.9130.171.434.1
Gain (Loss) on Sale of Assets------495.4
Other Unusual Items, Total-100.0-624.5581.2-57.1
In Process R&D Expenses-50.0-388.0---57.1
Other Unusual Items---85.0767.8--
EBT, INCLUDING UNUSUAL ITEMS6,525.25,349.55,408.25,889.3
Income Tax Expense1,455.71,001.81,319.61,204.5
Earnings from Continuing Operations5,069.54,347.74,088.64,684.8
NET INCOME5,069.54,347.74,088.64,684.8
NET INCOME TO COMMON INCLUDING EXTRA ITEMS5,069.54,347.74,088.64,684.8
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS5,069.54,347.74,088.64,684.8
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $64.25 USD +0.53

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.97 USD -0.12
AbbVie Inc $54.48 USD +0.43
Amgen Inc $122.01 USD +0.90
Bristol-Myers Squibb Co $49.32 USD +0.20
Teva Pharmaceutical Industries Ltd $55.05 USD +0.10
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 17.8x
Price/Sales 3.1x
Price/Book 3.7x
Price/Cash Flow 18.4x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.